Basilea Pharmaceutica AG

    Jurisdiction
    Switzerland
    LEI
    391200TTZP8EIPSJ5J20
    ISIN
    CH0011432447 (BSLN.SW)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    48 / 100
    Worse than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Fundamental strength relative to industry (Mohanram G-Value)
    7 / 7

    Profile

    Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Read full profile

    Fundamentals

    Net revenue
    €391.93M
    Gross margin
    70.2%
    EBIT
    €86.03M
    EBIT margin
    22.0%
    Net income
    €94.24M
    Net margin
    24.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €235.94M -39.8% €40.50M -57.0%
    €264.12M +11.9% €54.47M +34.5%
    €265.18M +0.4% €52.64M -3.4%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    CHF 5.00
    Ex date
    Payment date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: August 19, 2025 (Q2 2025)

    Add to watchlist

    Notifications